PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.14
D/E ratio at 50-90% of Drug Manufacturers - Specialty & Generic median of 0.16. Peter Lynch would verify if this conservative capital structure supports growth opportunities.
-2.91
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 0.46. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
15.56
Coverage of 15.56 versus zero Drug Manufacturers - Specialty & Generic median interest expense. Walter Schloss would verify if our leverage provides advantages.
2.87
Current ratio 1.25-1.5x Drug Manufacturers - Specialty & Generic median of 2.37. Philip Fisher would check if strong liquidity supports growth investments.
71.92%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.94%. Michael Burry would check for aggressive accounting and hidden risks.